AMGN [NASD]
Amgen Inc.
IndexDJIA S&P500 P/E24.02 EPS (ttm)10.16 Insider Own0.20% Shs Outstand563.27M Perf Week1.38%
Market Cap131.03B Forward P/E12.80 EPS next Y19.05 Insider Trans-1.24% Shs Float562.18M Perf Month-3.71%
Income5.72B PEG3.40 EPS next Q4.40 Inst Own81.60% Short Float3.54% Perf Quarter9.57%
Sales26.32B P/S4.98 EPS this Y-16.50% Inst Trans0.30% Short Ratio6.26 Perf Half Y18.78%
Book/sh1.67 P/B146.08 EPS next Y9.15% ROA9.30% Target Price249.25 Perf Year-1.88%
Cash/sh12.18 P/C20.02 EPS next 5Y7.07% ROE95.10% 52W Range198.64 - 258.45 Perf YTD8.44%
Dividend7.76 P/FCF30.19 EPS past 5Y0.10% ROI17.10% 52W High-6.03% Beta0.55
Dividend %3.18% Quick Ratio1.10 Sales past 5Y2.50% Gross Margin75.20% 52W Low22.27% ATR5.55
Employees24200 Current Ratio1.40 Sales Q/Q5.70% Oper. Margin30.40% RSI (14)50.93 Volatility2.05% 2.32%
OptionableYes Debt/Eq40.23 EPS Q/Q-5.40% Profit Margin21.70% Rel Volume0.69 Prev Close243.96
ShortableYes LT Debt/Eq39.31 EarningsApr 27 AMC Payout70.80% Avg Volume3.18M Price242.87
Recom2.50 SMA200.36% SMA500.39% SMA2008.07% Volume653,841 Change-0.45%
Feb-09-22Reiterated Wells Fargo Equal Weight $210 → $250
Feb-09-22Reiterated Oppenheimer Outperform $272 → $285
Feb-09-22Reiterated Morgan Stanley Equal-Weight $235 → $238
Feb-09-22Reiterated Jefferies Buy $266 → $280
Feb-09-22Reiterated Barclays Equal Weight $228 → $233
Jan-05-22Downgrade BofA Securities Buy → Neutral $285 → $255
Dec-09-21Resumed Wells Fargo Equal Weight $210
Dec-06-21Initiated Goldman Buy $258
Nov-19-21Initiated BMO Capital Markets Market Perform $228
Sep-23-21Downgrade Daiwa Securities Outperform → Neutral $220
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $280 → $251
Dec-29-20Initiated Daiwa Securities Buy $300
Oct-28-20Initiated UBS Neutral $232
Oct-26-20Upgrade Raymond James Mkt Perform → Outperform $255
Oct-12-20Upgrade Truist Hold → Buy
Oct-09-20Downgrade Truist Buy → Hold $251
Oct-09-20Downgrade Bernstein Outperform → Mkt Perform
Oct-08-20Downgrade Raymond James Outperform → Mkt Perform
Apr-15-20Resumed Guggenheim Neutral
Mar-31-20Initiated Wolfe Research Peer Perform
May-17-22 06:15AM  
May-13-22 02:29PM  
08:33AM  
May-12-22 12:45PM  
08:00AM  
06:12AM  
May-10-22 02:05PM  
May-06-22 04:00PM  
12:43PM  
07:33AM  
May-05-22 11:00PM  
03:33PM  
08:20AM  
May-04-22 01:39PM  
May-03-22 03:01PM  
10:42AM  
06:20AM  
06:01AM  
May-02-22 09:00AM  
May-01-22 06:45AM  
Apr-29-22 11:20AM  
Apr-28-22 04:21PM  
01:44PM  
01:33PM  
10:44AM  
09:33AM  
06:30AM  
04:51AM  
02:07AM  
Apr-27-22 05:28PM  
05:25PM  
05:03PM  
04:52PM  
04:34PM  
04:34PM  
04:26PM  
04:01PM  
09:00AM  
08:02AM  
06:01AM  
Apr-26-22 11:44AM  
11:15AM  
05:50AM  
Apr-25-22 11:49AM  
08:44AM  
06:18AM  
Apr-22-22 04:00PM  
09:53AM  
07:50AM  
Apr-21-22 06:00PM  
Apr-20-22 12:10PM  
08:23AM  
Apr-19-22 06:15PM  
03:00PM  
10:57AM  
09:15AM  
06:30AM  
Apr-18-22 04:00PM  
12:53PM  
Apr-14-22 10:38AM  
05:55AM  
Apr-13-22 06:00PM  
Apr-12-22 02:09PM  
10:23AM  
Apr-11-22 06:15PM  
12:21PM  
Apr-10-22 12:00PM  
Apr-08-22 03:17PM  
Apr-06-22 10:15AM  
Apr-05-22 06:00PM  
Apr-04-22 06:15PM  
Apr-03-22 06:10AM  
Apr-01-22 10:45AM  
Mar-29-22 06:00PM  
12:23PM  
Mar-28-22 06:15PM  
Mar-25-22 09:00AM  
Mar-24-22 08:38AM  
06:09AM  
Mar-23-22 05:20PM  
Mar-22-22 06:00PM  
Mar-21-22 06:15PM  
09:05AM  
Mar-20-22 08:03AM  
Mar-17-22 02:03PM  
Mar-16-22 11:15AM  
09:09AM  
Mar-14-22 06:00PM  
03:02PM  
Mar-11-22 12:06PM  
11:09AM  
Mar-10-22 04:00PM  
Mar-09-22 11:30AM  
Mar-08-22 06:00PM  
04:30PM  
Mar-07-22 09:11PM  
04:00PM  
Mar-06-22 10:45AM  
Mar-02-22 06:00PM  
04:15PM  
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Graham Jonathan PEVP, Gen. Counsel & Secy.May 10Sale241.8113,5003,264,45437,333May 10 07:45 PM